FIG. 4.
The ESAT-6-, CFP-10-, and PPD-specific SFCs of ELISPOT assay with ATB patients and HC. Ex vivo ELISPOT assay was performed on 46 ATB patients receiving anti-TB treatment equal to or shorter than 1 month and 50 healthy individuals. The short transverse line represents median of SFCs in different subgroups.